<DOC>
	<DOCNO>NCT00325390</DOCNO>
	<brief_summary>To evaluate efficasy safety SR25990C ( load dose:300mg , maintenance dose:75mg/day ) comparison standard Japanese treatment ( ticlopidine ) patient acute coronary syndrome without ST-segment elevation plan percutaneous coronary intervention ( include stenting ) .</brief_summary>
	<brief_title>Efficacy Safety Patients With Acute Coronary Syndrome Without ST-Segment Elevation</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Patients age 20 , admit hospital symptom suspect represent acute coronary syndrome define unstable angina acute MI without ST segment elevation great 1 mm eligible study meet follow criterion : ( 1 ) Clinical history consistent new onset worsening pattern characteristic ischemic chest pain occur rest minimal exercise ( last longer 5 minute require sublingual nitroglycerin relief pain within 24 hour registration ) . ( 2 ) Patients meet either follow criterion ECG change compatible new ischemia [ e.g . ST depression ( least 1 mm ) , T wave inversion ( least 2 mm ) , hyperacute peak T wave 2 contiguous lead ] . already elevated CK least twice upper limit normal CKMB Troponin I T upper limit normal positive qualitative test Troponin T. ( 3 ) A percutaneous coronary intervention plan within 96 hour first study drug administration A ) Factors affect participation study : ( 1 ) Previous disable stroke ( 2 ) Previous intracranial hemorrhage hemorrhagic stroke ( 3 ) Severe comorbid condition patient expect survive 1 month ( 4 ) NYHA Class IV heart failure ( 5 ) Uncontrolled hypertension ( 6 ) Requirement use oral anticoagulant , non study antiplatelet agent ( include ticlopidine ) NSAIDs ( exclude unum sumatur ) , study period , B ) Factors related ASA and/or ticlopidine treatment : ( 1 ) Use ticlopidine within 1 week prior randomization ( 2 ) History ASA ticlopidine intolerance allergy ( 3 ) Contraindications ASA ticlopidine</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>SR25990C</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>NSTEACS</keyword>
</DOC>